A61K 31/48
Ergoline derivatives
Official title: Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K31/48 (Ergoline derivatives) appears on 445 US grants and 647 published applications in this corpus.
Search patents in A61K- Granted patents
- 445
- Published applications
- 647
- Assignees
- 280
- Inventors
- 911
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 5 | 0 |
| 1986 | 3 | 0 |
| 1987 | 9 | 0 |
| 1988 | 6 | 0 |
| 1989 | 9 | 0 |
| 1990 | 8 | 0 |
| 1991 | 8 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 5 | 0 |
| 1996 | 7 | 0 |
| 1997 | 23 | 0 |
| 1998 | 24 | 0 |
| 1999 | 21 | 0 |
| 2000 | 7 | 0 |
| 2001 | 17 | 7 |
| 2002 | 17 | 18 |
| 2003 | 9 | 34 |
| 2004 | 4 | 22 |
| 2005 | 3 | 17 |
| 2006 | 1 | 19 |
| 2007 | 5 | 14 |
| 2008 | 1 | 14 |
| 2009 | 2 | 15 |
| 2010 | 5 | 17 |
| 2011 | 5 | 11 |
| 2012 | 7 | 8 |
| 2013 | 10 | 25 |
| 2014 | 10 | 26 |
| 2015 | 14 | 54 |
| 2016 | 26 | 44 |
| 2017 | 17 | 28 |
| 2018 | 26 | 30 |
| 2019 | 17 | 25 |
| 2020 | 14 | 28 |
| 2021 | 12 | 27 |
| 2022 | 14 | 26 |
| 2023 | 12 | 50 |
| 2024 | 10 | 42 |
| 2025 | 13 | 25 |
| 2026 | 16 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bacterial DNA gyrase inhibitors and methods of use thereof25 Aug 2026US 12,714,692 B2The Florida International University Board of Trustees
- Compositions of matter and pharmaceutical compositions28 Jul 2026US 12,691,098 B2Atai Therapeutics, Inc.
- Compositions and methods for improving cognitive function28 Jul 2026US 12,691,130 B2Diamond Therapeutics Inc.
- Compositions of matter and pharmaceutical compositions21 Jul 2026US 12,685,722 B2Atai Therapeutics, Inc.
- Composition and method for treating metabolic disorders30 Jun 2026US 12,668,590 B2VeroScience LLC
- Composition and Method for Treating Metabolic Disorders17 Sep 2026US 2026/0274834 A1VeroScience LLC
- Compositions comprising lysergic acid diethylamide, optionally in combination with n-acylethanolamines and uses thereof3 Sep 2026US 2026/0256773 A1Clearmind Labs Corp.
- Lipid prodrugs of bromolysergide and uses thereof20 Aug 2026US 2026/0242371 A1Seaport Therapeutics, Inc.
- Compositions and Uses Thereof13 Aug 2026US 2026/0232633 A1Purposeful IKE
- Compositions and Uses Thereof13 Aug 2026US 2026/0232661 A1Purposeful IKE
Most cited
By later US patents
- Treatment of female sexual dysfunction239US 5,877,216 AVivus, Inc. · 1999
- Treatment of female sexual dysfunction233US 6,294,550 B1Asivi, LLC · 2001
- Treatment of female sexual dysfunction212US 6,306,841 B1Asivi, LLC · 2001
- Pharmaceutical formulation containing gelling agent198US 8,337,888 B2Purdue Pharma L. P. · 2012
- Aerosol formulations containing propellant 134a and fluticasone propionate159US 5,658,549 AGlaxo Group Limited · 1997